[Bloomberg Government] Backlash on Rising Drug Prices Led by Cancer Doctors, Insurers

By Robert Langreth May 7, 2014   The backlash over surging drug prices is starting to take hold. With the average cost of branded cancer drugs doubling over […]

Read more

[Georgia Health News] Hepatitis C: The high cost of a cure

By Andy Miller May 6, 2014   Probably the biggest ethical dilemma now confronting the health care world involves two expensive new drugs to treat hepatitis […]

Read more

[The New Yorker] BIOTECH’S HARD BARGAIN

BY JAMES SUROWIECKI April 28 Issue   Few people have done better in the recent stock boom than biotech investors. Biotech was the best-performing market sector last […]

Read more

[Washington Post] An $84,000 hepatitis drug is giving states and insurers a major headache

By Jason Millman April 28, 2014   The new hepatitis C drug Sovaldi is being hailed as a potential breakthrough treatment for a disease that affects […]

Read more